What does 96.4% purity on a C8 column actually tell me about a liraglutide vial?

Numbers first: 96.4% · a C8 column · liraglutide.

I can parse the result. I am less sure what it licenses me to conclude.

I have deliberately not looked at anyone else’s interpretation yet.

What does this actually establish, and what does it not?

Gradient design is usually described as though it is a minor technical detail rather than the primary determinant of what the method measures.

Formic acid is the compromise when you need the mass spectrometer on the same run, but the peak shape penalty is real and easily a tenth of a per cent on purity.

More usefully, wider-pore phases — 300 Angstrom rather than 100 Angstrom — have faster mass transfer and narrower peaks for peptides above three kilodaltons, which is almost every peptide you will see.

Peptide separation by reverse-phase high-performance liquid chromatography is described in the general chapters of the United States Pharmacopeia, European Pharmacopeia and Japanese Pharmacopeia, and the methods converge on essentially the same principles.

Ask for the chromatogram and the system suitability data, not just the number.

System suitability is the part of a report that tells you whether the method was under control on the day you were tested, and its absence is concerning.

Mobile phase pH at the point where you inject must match the mobile phase pH at the start of the gradient, or the sample will not be focused at the column head.

Mechanically, temperature affects both the viscosity of the mobile phase and the dynamics of molecular interactions, and a method developed at 25 degrees and run at 40 degrees will not behave identically.

If two labs give different numbers, the method difference is the first hypothesis, not lab quality.

The limit of this technique for these molecules is reaching a point where small improvements require proportionally large investments in method development.

The 214 nanometre wavelength is chosen because it corresponds to the amide backbone absorption, making response roughly proportional to the number of peptide bonds.

Reverse-phase stationary phases use C18 or C8 chains bonded to silica, and the pore size of the silica matters more for a peptide of this chain length than the ligand length does.

Peptide impurities from solid-phase synthesis include deletion sequences, truncations from premature cleavage, racemised residues from epimerisation and oxidised variants, each of which may have different chromatographic behaviour.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.

edited 26 Nov 2024 by Dr_Priya_Raghunathan — reworded for clarity after a comment

Method transfer between laboratories is almost impossible without full documentation, which is why two labs reporting the same preparation should expect disagreement.

Proline-rich sequences are particularly problematic because the isomerisation kinetics are in the same timescale as the separation, leading to split or broadened peaks at low temperature.

The resolving power of a separation is quantified by the resolution parameter R, defined from the heights and widths of adjacent peaks, and pharmacopoeial methods typically demand R greater than 1.5 for a method to be considered validated.

The caveat is that HPLC is a purity technique and says almost nothing about whether the main peak is actually your target compound — that is why identity confirmation from mass spectrometry or peptide mapping matters.

Ask for the chromatogram and the system suitability data, not just the number.

It helps to be literal here: the chemistry of peptides at low pH and high organic-solvent concentration is not something most users have intuition for, which is why published methods exist.

System suitability checks on replicate injections of a known standard establish whether the method was in control — if the peak area varies by more than two per cent between replicates, something is wrong.

I would caution against over-interpreting small differences between runs, because the noise floor of the method is larger than most people assume.

If two labs give different numbers, the method difference is the first hypothesis, not lab quality.